Vor Biopharma Inc. (VOR) - Q1 2026 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended March 31, 2026. Vor Biopharma Inc. is a clinical-stage biopharmaceutical company focused on developing telitacicept, a dual-target recombinant fusion protein for autoimmune diseases. In June 2025, the company in-licensed telitacicept from RemeGen Co., Ltd. for exclusive rights outside Greater China. The company is currently conducting global Phase 3 clinical trials for telitacicept in generalized myasthenia gravis (gMG) and Sjögren's disease (SjD). The company has no commercial revenue and relies on capital raises to fund operations.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(219.6) million | $(32.5) million |
| Operating Expenses | $35.2 million | $33.3 million |
| Cash, Cash Equivalents & Marketable Securities | $491.5 million | $52.5 million (Total cash) |
| Accumulated Deficit | $(1,372.6) million | $(489.5) million |
| Net Cash Used in Operating Activities | $(38.2) million | $(31.1) million |
| Net Cash Provided by Financing Activities | $74.9 million | $(0.6) million |
Note: All figures in millions unless otherwise noted. Q1 2025 cash figures adjusted for context; Q1 2026 includes significant investment in marketable securities.
Material Changes vs. Prior Period
- Net Loss Expansion: Net loss increased significantly to $219.6 million from $32.5 million in Q1 2025. This was primarily driven by a $188.4 million non-cash charge related to the change in fair value of warrant liabilities.
- Operating Expenses: Total operating expenses increased slightly to $35.2 million.
- R&D Expenses: Decreased to $17.6 million (from $26.7 million) due to the wind-down of legacy programs (Trem-cel, VCAR33) and reduced personnel/manufacturing costs, partially offset by $12.3 million in new spend for telitacicept programs.
- G&A Expenses: Increased to $17.6 million (from $6.6 million), driven by a $7.4 million increase in stock-based compensation and higher personnel costs for new executives.
- Liquidity Position: Cash and marketable securities grew to $491.5 million, supported by a $74.9 million private placement in March 2026 and proceeds from prior year offerings. The company invested heavily in marketable securities ($276.5 million purchases) during the quarter.
- Capital Structure: The company completed a 1-for-20 reverse stock split in September 2025. As of March 31, 2026, there were 54.2 million shares of common stock outstanding.
Guidance, Outlook, and Risks
- Liquidity Outlook: Management expects existing cash, cash equivalents, and marketable securities ($491.5 million) to fund operations into early 2029.
- Clinical Milestones:
- gMG: Global Phase 3 trial is recruiting; topline data anticipated in the first half of 2027.
- SjD: Global Phase 3 trial initiated in March 2026; targeting ~250 patients.
- Key Risks:
- Warrant Liability Volatility: The company has significant warrant liabilities ($638.5 million as of March 31, 2026) classified as liabilities. Changes in the company's stock price directly impact the fair value of these warrants, causing significant volatility in reported net loss.
- Capital Requirements: The company expects to incur significant losses for the foreseeable future and will require substantial additional funding.
- Third-Party Dependence: Reliance on RemeGen for data from China and third-party manufacturers for clinical supply.
- Regulatory Uncertainty: No assurance that FDA will accept data from RemeGen's trials or that the company will obtain approval for telitacicept.
Investor Verification Checklist
- Verify the fair value methodology used for the $638.5 million warrant liability and its sensitivity to stock price fluctuations.
- Confirm the cash runway assumptions used to project funding into early 2029, given the high burn rate.
- Review the terms of the March 2026 private placement with TCGX affiliates, noting the related party transaction status.
- Assess the progress of patient enrollment in the global Phase 3 trials for gMG and SjD against management's targets.
- Monitor the status of the 2025 Warrants (PIPE and RemeGen), including exercise activity and potential dilution.